Navigation Links
Silence Therapeutics' Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
Date:11/10/2010

tatic processes that involve blood flow to the lung," stated Klaus Giese, Ph.D., chief scientific officer at Silence Therapeutics.  "Importantly, these data provide us with evidence that Atu027, which targets vascular endothelial cells, may be modulating not only the tumor vasculature itself, but the pulmonary vasculature as well."

"We are very pleased to be able to continue to identify the mechanisms that drive Atu027's therapeutic activity while concurrently advancing the product through its ongoing Phase 1 study.  Building this collection of novel data on Atu027 will only serve to inform our ongoing development efforts and allow us to maximize the opportunity for success with this program," said Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.

Atu027, a liposomal AtuRNAi™ formulation in clinical development for systemic cancer indications, is one of the most clinically advanced RNAi therapeutics in the area of oncology.  In June 2009, Silence initiated an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid (malignant) tumors involving single, as well as, repeated intravenous administration.  The study is expected to be completed early in the second half of 2011.

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular upta
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Niagara Thermal Products is proud to announce that ... ("B3") as the critical thermal component supplier in support ... Corps of Engineers.  B3 has developed the only comprehensive ... destroys VOCs and other chemical pollutants, allergens and organic ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... PharmAthene, Inc.,(Amex: PIP ) a biodefense ... announced that the Delaware Chancery Court,today issued a ... dismiss,PharmAthene,s complaint, which alleges that it has a ... SIGA,s drug candidate, SIGA-246. SIGA,s,request to dismiss the ...
... Helix BioPharma Corp.,(TSX: HBP/Frankfurt: WKN 918846) announced today ... Inc. ("KBI") to develop a process for,preparing L-DOS47 ... clinical testing., "This new arrangement advances the ... with L-DOS47," said John Docherty, Helix,s,president. "The lyophilized ...
... Bristol-Myers Squibb,Company (NYSE: BMY ) will announce ... on Thursday, January 31. During a 10 a.m. (ET) ... information and will,address inquiries from investors and analysts., ... to a live,webcast of the call at http://www.bms.com/ir ...
Cached Biology Technology:Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthene's Legal Action in Breach of Contract Lawsuit Against SIGA 2Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format 2Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format 3
(Date:4/24/2014)... at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified the ... to discriminate between viral and endogenous RNAs in ... take control of cellular metabolism and hijack cellular ... process is dependent on viral RNA molecules that ... RNA viruses) and/or newly synthesized in the host ...
(Date:4/24/2014)... With a new generation of military veterans returning home ... become a prominent concern in American medical institutions and ... 35 percent of personnel deployed to Iraq and Afghanistan ... South Carolina School of Medicine is shedding light on ... and surprising ways. , The rise in PTSD has ...
(Date:4/23/2014)... pair of bioethics experts have added "playwright" to their ... in grappling with an onslaught of ethical issues as ... the human genome was first sequenced. , Until ... W. Bush have been performed for, and by, their ... conferences, meetings and in classrooms. With Oxford University ...
Breaking Biology News(10 mins):Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3New study links inflammation in those with PTSD to changes in microRNA 2New study links inflammation in those with PTSD to changes in microRNA 3Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3
... For the first time, neuroscientists have systematically identified the ... communications network that supports brain function. Their work, ... in Human Neuroscience , has major implications for understanding ... have the greatest influence over all other connections, the ...
... 10, 2014In a study published today in ... Ken Shepard, professor of electrical engineering and biomedical ... professor of biological sciences at Columbia University, has ... modern computers and communications devices, can be used ...
... Feb. 10, 2014 The Translational Genomics Research Institute (TGen) ... to the brain, according to a first-of-its-kind study published in ... of genetic targets uncovered by TGen now can be used ... therapies for the estimated 45,000 patients in the U.S. each ...
Cached Biology News:How our brain networks: Research reveals white matter 'scaffold' of human brain 2How our brain networks: Research reveals white matter 'scaffold' of human brain 3Chips that listen to bacteria 2TGen study uncovers possible genetic markers in breast cancer that spreads to the brain 2
... the Adept CE 4100 high pressure dual piston ... wavelength detector for added flexibility. The ... and interface unit, CE 4901., The CE 4901 ... be used with Windows 98 and 2000, offers ...
...
... Chromosomal Grade Agarose was developed specifically for pulsed field separations of DNA larger than 2, ... megabase pairs. This ... ... Megabase DNA separations done in Chromosomal Grade, ...
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
Biology Products: